Advertise on podcast: Oncology Spotlight

New FDA approvals and practice-relevant Phase III data feature in this week’s Oncology Updates from ONCOassist. Dr. Stephanie Haddad, Hematology/Oncology Fellow and Academic Chief Fellow at UT Health San Antonio/Mays Cancer Center, covers: 🔹 ER+/HER2− Breast Cancer: The FDA approved Imlunestrant plus Abemaciclib for adults with ESR1-mutated advanced or metastatic breast cancer following progression after prior endocrine therapy. In Phase III EMBER-3, median PFS was 11.1 months with the combination versus 5.5 months with imlunestrant alone (HR 0.53). 🔹 EGFR-Mutated NSCLC: Phase III ADVANCE evaluated a chemotherapy-free strategy of aumolertinib plus radiotherapy versus concurrent chemoradiotherapy in unresectable Stage III EGFR-mutated NSCLC. Median PFS was 34 months versus 7.4 months (HR 0.15), although the randomized population included only 43 patients and overall survival remains immature. 🔹 Biliary Tract Cancer: Five-year follow-up from Phase III ASCOT confirmed a sustained survival benefit with adjuvant S-1 following resection. Five-year OS was 64% with S-1 versus 52% with observation (HR 0.72), with median OS of 8.2 versus 5.9 years. 🔹 Advanced Renal Cell Carcinoma: The FDA approved Belzutifan plus Lenvatinib for adults with advanced RCC with a clear cell component following prior PD-1 or PD-L1 inhibitor therapy. The approval was based on LITESPARK-011, which enrolled 747 patients. Reference Links: https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-inluriyo-imlunestrant-combination-verzeniohttps://www.nature.com/articles/s41392-026-02891-2  https://ascopubs.org/doi/10.1200/JCO-26-00017   https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-combination-lenvatinib-advanced-renal-cell-carcinoma-clear-cell-component  📲 Oncology at your fingertips. Access the ONCOassist app: 📥 iOS, Android & Webapp: https://campaign.oncoassist.com/social-y

🎥 Latest Oncology News Four developments across breast cancer, lung cancer, multiple myeloma and prostate cancer. In this episode of Oncology Updates from ONCOassist, Dr. Stephanie Haddad reviews: 🔹 HER2+ metastatic breast cancer: The European Commission has approved Enhertu (Trastuzumab deruxtecan) plus Pertuzumab as first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer. In Phase III DESTINY-Breast09, the combination reduced the risk of disease progression or death by 44% versus THP, with median PFS of 40.7 vs 26.9 months. 🔹 Relapsed/refractory multiple myeloma: Phase III CERVINO topline results showed an ORR of 74.0% with investigational Etentamig versus 45.7% with standard available therapies, alongside a 60% reduction in the risk of progression or death. 🔹 Prostate cancer: The randomized STAMINA trial evaluated a 12-month supervised programme combining exercise, dietary advice and behavioural support for men receiving androgen deprivation therapy. Dr. Haddad reviews its reported effects on prostate cancer-specific quality of life, fatigue and overall cancer-related quality of life. 🔹 HER2-mutated NSCLC: The FDA granted accelerated approval to Sevabertinib for adults with locally advanced or metastatic non-squamous NSCLC harbouring HER2/ERBB2 activating mutations, based on response rate and duration-of-response data from SOHO-01. Reference Links: https://www.astrazeneca.com/media-centre/press-releases/2026/enhertu-approved-in-eu-for-1l-her2-positive-mbc.html   https://news.abbvie.com/2026-09-03-AbbVie-Announces-Positive-Topline-Results-from-the-Phase-3-CERVINO-Trial-Showing-Etentamig-Significantly-Improved-Response-Rate-and-Progression-Free-Survival-in-Patients-with-Relapsed-Refractory-Multiple-Myeloma   https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00304-9/fulltext   https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small  📲 Oncology at your fingertips. Access the ONCOassist app: 📥 iOS, Android & Webapp: https://campaign.oncoassist.com/social-y

🎥 Latest Oncology News From a landmark mRNA-based individualized neoantigen therapy result in melanoma to an important advance in metastatic pancreatic cancer, this edition brings several major developments across oncology. Dr. Stephanie Haddad, Hematology/Oncology Fellow and Academic Chief Fellow at UT Health San Antonio/Mays Cancer Center, breaks down four updates oncology professionals should know. The FDA approved Daraxonrasib, a RAS inhibitor, for metastatic pancreatic adenocarcinoma following at least one prior systemic therapy or for patients not eligible for multi-agent chemotherapy. In RASolute 302: Median OS: 13.2 vs 6.7 months Median PFS: 7.2 vs 3.6 months Response rate: 30% vs 11% OS hazard ratio: 0.40 The European Commission approved Sacituzumab Govitecan + Pembrolizumab for first-line PD-L1-positive metastatic triple-negative breast cancer with CPS ≥10. Together with its recent monotherapy approval for patients who are not candidates for immunotherapy, Sacituzumab govitecan-based options now extend across PD-L1 status in first-line metastatic TNBC. In ASCENT-04, the combination reduced the risk of progression or death by 35%. The Phase III INTerpath-001 trial of Intismeran autogene + Pembrolizumab met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival in completely resected Stage IIB–IV melanoma. The study represents the first Phase III readout for an individualized neoantigen therapy or mRNA cancer therapy and the first to outperform Pembrolizumab alone in the adjuvant setting. Detailed results are expected at an upcoming congress, while overall survival remains immature. New quality-of-life and safety data from the Phase III ALINA trial build on the previously reported disease-free survival benefit with adjuvant Alectinib in resected ALK-positive NSCLC. Treatment discontinuation was lower with Alectinib than chemotherapy (5% vs 13%), while quality of life improved early and was maintained for more than two years. Reference Links:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma   https://www.gilead.com/news/news-details/2026/european-commission-expands-role-of-gileads-trodelvy-in-first-line-metastatic-triple-negative-breast-cancer-across-pd-l1-status   https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/   https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00283-4/fulltext  --------------------------------------------------- 📲 Oncology at your fingertips. Access the ONCOassist app: 📥 iOS, Android & Webapp: https://campaign.oncoassist.com/social-y 🧬 Daraxonrasib in metastatic pancreatic cancer🎗️ Sacituzumab Govitecan + Pembrolizumab in TNBC🧬 Landmark Phase III mRNA melanoma result🫁 ALINA: Alectinib in ALK+ NSCLC

👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, treatment protocols, and calculators!  🔬In this episode of Oncology Spotlight - Expert Insights, Dr Yüksel Ürün, medical oncologist at Ankara University, reviews key studies presented at the ASCO Genitourinary Cancers Symposium, 2026. The discussion focuses on clinically relevant trial results across bladder cancer, kidney cancer, and metastatic prostate cancer, highlighting data that may influence treatment decisions in daily oncology practice. Key Studies Discussed:• KEYNOTE-B15 trial – Enfortumab vedotin + pembrolizumab in muscle-invasive bladder cancer- https://www.asco.org/abstracts-presentations/256834 • LITESPARK-011 – Belzutifan + lenvatinib after IO therapy in kidney cancer - https://www.asco.org/abstracts-presentations/256659  • LITESPARK-022 – Adjuvant belzutifan + pembrolizumab in high-risk kidney cancer - https://www.asco.org/abstracts-presentations/256660  • BRCAAway trial – Abiraterone + olaparib combination in metastatic castration-resistant prostate cancer - https://www.asco.org/abstracts-presentations/256832  Key Clinical Takeaways ✔ EV + pembrolizumab improves event-free survival in muscle-invasive bladder cancer ✔ Belzutifan combinations show promising activity in renal cell carcinoma ✔ Combination PARP inhibitor + ARPI therapy may significantly extend survival in selected mCRPC patients A must-watch for oncologists and trainees looking for clear, clinically relevant takeaways from the latest GU oncology trials presented at ASCO GU26. 📌 CHAPTERS & TIMESTAMPS 🎙 00:08 – Introduction 👨‍⚕️ 00:14 – Meet Dr. Yüksel Ürün 🧬 00:20 – KEYNOTE-B15: EV + Pembrolizumab in Muscle-Invasive Bladder Cancer 📊 02:30 – Event-Free Survival & Pathologic Response Results ⚕️ 05:18 – LITESPARK-011: Belzutifan + Lenvatinib in RCC 📈 06:20 – Progression-Free Survival Improvement 💊 08:47 – LITESPARK-022: Adjuvant Belzutifan + Pembrolizumab 📉 10:01 – Disease-Free Survival Outcomes 🧪 11:34 – BRCAAway Trial: PARP + ARPI Combination 📊 13:00 – Survival Benefit in HRD-Mutated Prostate Cancer 🔬 15:16 – Clinical Implications for Practice 👋 15:24 – Closing Thoughts 📢 JOIN THE CONVERSATION! ❓Drop your thoughts in the comments below!📲 Oncology at your fingertips. Download the ONCOassist app: 📥 iOS: https://apple.co/4iuMxfS 📥 Android: https://bit.ly/oncoassistonandroid 📥Webapp: https://bit.ly/ONCOassistOnWeb 🚀 SUBSCRIBE to the ONCOassist Youtube Channel for more expert insights!🔔 Turn on notifications so you never miss an episode. 📌 FOLLOW US FOR UPDATES: 📍 LinkedIn: https://bit.ly/oncoassistlinkedin 📍 Twitter/X: https://bit.ly/oncoassisttwitter

👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, treatment protocols, and calculators!  🔬In this episode of Oncology Spotlight, Dr. Shaqil Kassam shares a powerful perspective from the front lines of community oncology in Canada. From drug access delays in publicly funded systems to the real-world challenges of administering bispecific therapies outside academic centers, this conversation dives into the complexity of modern oncology. We also explore: Community vs academic oncology – what truly differs? The global equity gap in cancer care How AI is already transforming clinic workflows and pathology The real challenges behind sequencing new therapies Why equitable access remains the biggest global barrier  This is a must-watch for oncologists, trainees, and healthcare leaders navigating rapid innovation in constrained systems. Check out the MedOncNow podcast: https://medoncnow.podbean.com/ 📌 CHAPTERS & TIMESTAMPS 🏥 00:00 – The Biggest Issue: Drug Access in Public Healthcare 🎙️ 00:36 – Introduction & Guest Overview 👨‍⚕️ 01:07 – Dr. Kassam’s Journey to Medical Oncology 🌍 03:29 – Community vs Academic Oncology Explained 📊 06:33 – Are 80% of Patients Treated in Community Settings? 🤝 08:00 – Collaboration Between Community & Academic Oncologists 🎧 08:44 – The MedOncNow Podcast: Why It Started 💊 10:49 – Practical Implementation of New Cancer Drugs 🌎 13:07 – The Future of Oncology in Canada ⚖️ 16:05 – Equity: Canada’s Strength & Global Weakness 🌍 17:05 – Barriers to Global Cancer Care 🧠 21:40 – AI in Oncology: From Dictation to Digital Pathology 🎓 25:14 – Advice for Future Oncologists 📢 JOIN THE CONVERSATION! ❓Drop your thoughts in the comments below!📲 Oncology at your fingertips. Download the ONCOassist app: 📥 iOS: https://apple.co/4iuMxfS 📥 Android: https://bit.ly/oncoassistonandroid 📥Webapp: https://bit.ly/ONCOassistOnWeb 🚀 SUBSCRIBE to the ONCOassist Youtube Channel for more expert insights!🔔 Turn on notifications so you never miss an episode. 📌 FOLLOW US FOR UPDATES: 📍 LinkedIn: https://bit.ly/oncoassistlinkedin 📍 Twitter/X: https://bit.ly/oncoassisttwitter

🔬In this episode, Dr. Shreyas Kalantri shares his journey from medical training in India to academic oncology in the United States, and reflects on what truly defines progress in cancer care. The conversation dives deep into quality of life as a critical endpoint, disparities in immunotherapy access, the role of academic research, global oncology collaboration, and how AI can reshape oncology workflows. Dr. Kalantri also discusses his work with the HemOnc Fellows Network and ASCO’s Training & Early Career Advisory Group, highlighting the importance of mentorship and democratizing oncology education worldwide. This episode is essential listening for oncologists, trainees, and healthcare professionals navigating the rapidly evolving oncology landscape. 🔹 Key Topics Covered Why quality of life should contextualize survival outcomes Gaps in quality-of-life reporting in clinical trials The HemOnc Fellows Network Academic oncology vs community practice Global oncology and trainee mentorship initiatives AI, digital tools, and the future of oncology workflows Advice for trainees considering a career in oncology 🎬A must-watch episode for oncologists, trainees, and healthcare leaders shaping the future of cancer care. Connect with Shreyas Kalantri here: https://www.linkedin.com/in/shreyaskalantrimd/  📲 Oncology at your fingertips. Download the ONCOassist app: 📥 iOS: https://apple.co/4iuMxfS 📥 Android: https://bit.ly/oncoassistonandroid 📥Webapp: https://bit.ly/ONCOassistOnWeb 📌 FOLLOW US FOR UPDATES: 📍 LinkedIn: https://bit.ly/oncoassistlinkedin  📍 Twitter/X: https://bit.ly/oncoassisttwitter

👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, guidelines, and calculators!  🔬In this episode of Oncology Spotlight, we sit down with Katy Winckworth-Prejsnar, Director of the Global Program at NCCN (National Comprehensive Cancer Network). Katy offers a behind-the-scenes look at how NCCN’s guidelines are being adapted and implemented globally especially in low- and middle-income countries. She speaks on equity in access to cancer care, the challenges and opportunities in global implementation of NCCN Guidelines, and her unique path into oncology from a background in cancer genetics, community outreach, and health equity. 🧭 What you’ll learn in this episode: The mission of NCCN’s Global Program and its real-world impact How local adaptation of guidelines empowers low-resource settings Challenges in global cancer guideline dissemination Why policy, education, and advocacy are just as important as treatment Katy's powerful career journey into global oncology 🎧 Listen now and get inspired by how strategic collaboration and culturally informed adaptations are shaping the future of oncology around the world. Connect with Katy Winckworth-Prejsnar here: https://www.linkedin.com/in/katywinckworthprejsnar/ 📲 Oncology at your fingertips. Download the ONCOassist app: 📥 iOS: https://apple.co/4iuMxfS 📥 Android: https://bit.ly/oncoassistonandroid 📥Webapp: https://bit.ly/ONCOassistOnWeb 🚀 SUBSCRIBE to the ONCOassist Podcast for more expert insights! 🔔 Turn on notifications so you never miss an episode. 📌 FOLLOW US FOR UPDATES: 📍 LinkedIn: https://bit.ly/oncoassistlinkedin 📍 Twitter/X: https://bit.ly/oncoassisttwitter

👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, guidelines, and calculators!  🔬We sit down with Dr. Douglas Flora, Executive Medical Director at St. Elizabeth Healthcare and Editor-in-Chief of the AI in Precision Oncology Journal. In this episode, Dr. Flora shares how artificial intelligence is revolutionizing oncology, from early detection and precision treatment to the importance of human-centered care in an increasingly tech-driven world. Dr. Flora shares his candid insights on: How AI is being used in cancer detection and diagnostics The ethical challenges of integrating AI into clinical practice Why human connection remains at the heart of great cancer care Building emotionally intelligent care teams Leadership lessons from years on the front lines of oncology The mission behind the AI in Precision Oncology Journal 🧠 “AI won’t replace oncologists — it’ll empower them.” 📌 Don’t miss this powerful discussion on the intersection of compassion, tech, and cutting-edge cancer care. Connect with Dr. Douglas Flora here: https://www.linkedin.com/in/douglasflora/ Ai in Precision Oncology Journal: https://home.liebertpub.com/publications/ai-in-precision-oncology/679 📢 JOIN THE CONVERSATION! ❓Drop your thoughts in the comments below!📲 Oncology at your fingertips. Download the ONCOassist app: 📥 iOS: https://apple.co/4iuMxfS 📥 Android: https://bit.ly/oncoassistonandroid 📥Webapp: https://bit.ly/ONCOassistOnWeb 🚀 SUBSCRIBE to the ONCOassist Youtube Channel for more expert insights!🔔 Turn on notifications so you never miss an episode. 📌 FOLLOW US FOR UPDATES: 📍 LinkedIn: https://bit.ly/oncoassistlinkedin  📍 Twitter/X: https://bit.ly/oncoassisttwitter

👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, guidelines, and calculators!  🔬Step into the inspiring journey of Dr. Paul O’Brien, an Irish medical professional whose career has spanned continents and disciplines, from food science to clinical medicine, from China to Ireland, and from the wards to the digital frontlines of misinformation. In this episode of Oncology Spotlight, Dr. Paul O’Brien opens up about: - His unconventional journey into medicine - What training in China taught him about resilience - The open letter that made national headlines - Why physicians must reclaim the narrative on social media - The danger of pseudoscience & viral medical influencers - Practical use of AI in daily clinical decision-making - Mobilising support during the COVID-19 crisis 🧠 Insightful. Unfiltered. Timely. This is a must-watch for every clinician navigating the evolving intersection of medicine, media, and AI. Connect with Dr. Paul O’Brien here: https://www.linkedin.com/in/pgobrien/ Irish Examiner Article: https://www.irishexaminer.com/special-reports/arid-41419660.html 📌 CHAPTERS & TIMESTAMPS  ⏳[00:00] – Introduction & Welcome 👨‍⚕️ [00:28] – Dr. O’Brien’s Background  🌏 [00:54] – Inspiration to pursue a career in Medicine 🍱 [03:08] – Journey from Ireland to China and back again 💡 [06:00] – Choice or chance to study in China 🧠 [07:07] – Interest in Food Science 📺 [10:56] – Irish Examiner Feature & National Media Attention 🦠 [14:08] – Helping Ireland from China During COVID 📲 [14:54] – Content Creation & The Role of Doctors on Social Media 💻[17:05] – Gary Brecka, Brian Johnson & Combating Medical Misinformation 🏥 [19:20] – Healthcare Reform & Access Challenges in Ireland 🤖 [21:34] – Using AI Tools Like ChatGPT & Heidi in Clinical Practice 🔚 [24:29] – Final Thoughts & Closing Remarks 📲 Oncology at your fingertips. Download the ONCOassist app: 📥 iOS: https://apple.co/4iuMxfS 📥 Android: https://bit.ly/oncoassistonandroid 📥Webapp: https://bit.ly/ONCOassistOnWeb 🚀 SUBSCRIBE to the ONCOassist Youtube Channel for more expert insights!🔔 Turn on notifications so you never miss an episode. 📌 FOLLOW US FOR UPDATES: 📍 LinkedIn: https://bit.ly/oncoassistlinkedin  📍 Twitter/X: https://bit.ly/oncoassisttwitter

👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, guidelines, and calculators!  🎧 In this episode of Oncology Spotlight, we’re joined by Dr. Jiten Jaipuria, uro-oncologist and focal therapy specialist at Portsmouth Hospitals University NHS Trust, to explore a critical but often under-discussed topic: radiorecurrent prostate cancer. With recurrence becoming more common in the era of precision oncology, Dr. Jaipuria explains: How radiorecurrent prostate cancer is defined The role of the Phoenix criteria and PSA thresholds The growing importance of imaging (PSMA PET/MRI) How to approach salvage therapies like cryotherapy, HIFU, brachytherapy, and more Why a personalised treatment strategy is essential in recurrent cases 💬 “We have more tools than ever. It’s about picking the right one for the right patient.” This is a must-listen for urologists, oncologists, radiotherapists, and care teams managing recurrent prostate cancer cases. 📢 JOIN THE CONVERSATION! ❓ What do you think is the biggest challenge in oncology nursing today? Drop your thoughts in the comments below!📲 Oncology at your fingertips. Download the ONCOassist app: 📥 iOS: https://apple.co/4iuMxfS 📥 Android: https://bit.ly/oncoassistonandroid 📥Webapp: https://bit.ly/ONCOassistOnWeb 🌐 Learn more at: https://oncoassist.com/ 🚀 SUBSCRIBE to the ONCOassist Youtube Channel for more expert insights! 🔔 Turn on notifications so you never miss an episode. 📌 FOLLOW US FOR UPDATES: 📍 LinkedIn: https://bit.ly/oncoassistlinkedin  📍 Twitter/X: https://bit.ly/oncoassisttwitter  #OncologySpotlight #ProstateCancer #RadiorecurrentProstateCancer #FocalTherapy #SalvageTherapy #RoboticSurgery #UroOncology #PSMAPET #OncoAlert

👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, guidelines, and calculators!  🔬In this powerful episode, we’re joined by Dr. Akash Maniam, a UK-based medical oncologist whose work spans urological and breast cancers, with a strong focus on health equity, global access, and digital innovation. 🧠 From his experience in both the UK and the Caribbean, Dr. Maniam discusses: Structural gaps in global oncology systems How AI and digital health can bridge access inequalities Unique challenges refugees face when battling cancer Strategies for global collaboration and patient empowerment The founding and vision behind IUCS – International Urology Cancer Summit 🌍 With real-world insight and a passion for progress, Dr. Maniam shares practical ways we can make cancer care more inclusive, accessible, and future-ready. 📄 Further Reading – His Editorial: 🔗 “Refugees Have Cancer Too” – https://ecancer.org/en/journal/editorial/134-refugees-have-cancer-too 🌐 TeleHelp Ukraine – Website & Contact Information Website: https://telehelpukraine.com Contact Email: [email protected] Services: Provides free teleconsultations for Ukrainian patients, including oncology support.​ Download the ONCOassist app: 📥 iOS: https://apple.co/4iuMxfS 📥 Android: https://bit.ly/oncoassistonandroid 🚀 SUBSCRIBE to the ONCOassist Youtube Channel for more expert insights! 🔔 Turn on notifications so you never miss an episode. 📌 FOLLOW US FOR UPDATES: 📍 LinkedIn: https://bit.ly/oncoassistlinkedin  📍 Twitter/X: https://bit.ly/oncoassisttwitter

Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, guidelines, and calculators!  In this episode of Oncology Spotlight, we sit down with Aileen O'Meara, an Advanced Nurse Practitioner in Medical Oncology at St. Vincent's Hospital, Dublin, with over 30 years of experience in oncology nursing. Aileen shares invaluable insights into the changing landscape of cancer treatment, the role of advanced nurse practitioners, and the impact of immunotherapy on patient care. From discussing common immunotherapy side effects (irAEs) to new innovations in oncology nursing, this episode is packed with expert insights that every oncologist, nurse, and healthcare professional should hear. Listen now to learn: ✅ How oncology nursing has evolved over the years ✅ The role of Advanced Nurse Practitioners in cancer treatment ✅ Managing immune-related adverse events (irAEs) in patients ✅ How nurses differentiate side effects of immunotherapy vs. chemotherapy ✅ The latest oncology innovations & future treatment trends ✅ The role of AI & technology in supporting oncology nurses 🔹 Watch on Youtube: https://youtu.be/2by9BxX-tTA 📢 JOIN THE CONVERSATION! ❓ What do you think is the biggest challenge in oncology nursing today? Drop your thoughts in the comments below!📲 Oncology at your fingertips. Download the ONCOassist app: 📥 iOS: https://apple.co/4iuMxfS 📥 Android: https://bit.ly/oncoassistonandroid 🚀 SUBSCRIBE to the ONCOassist Youtube Channel for more expert insights! 🔔 Turn on notifications so you never miss an episode. 📌 FOLLOW US FOR UPDATES: 📍 LinkedIn: https://bit.ly/oncoassistlinkedin 📍 Twitter/X: https://bit.ly/oncoassisttwitter We hope you enjoyed the episode.  Thank you for being a part of ONCOassist.

In this episode of the Oncology Spotlight podcast, we are honored to host Prof. Keith Kerr, a Consultant Pathologist at Aberdeen Royal Infirmary and Honorary Professor at the University of Aberdeen. With over 35 years of experience in thoracic pathology, Prof. Kerr is a globally recognized expert in non-small cell lung cancer (NSCLC), particularly in predictive and diagnostic biomarkers, immunotherapy, and personalized medicine. Join us as Prof. Kerr shares his remarkable journey from medical school to becoming a leading pathologist specializing in thoracic oncology. In this insightful conversation, he delves into: His Path to Pathology: Discover what led Prof. Kerr to specialize in thoracic oncology and how a pivotal research project in lung cancer set the course for his distinguished career. Understanding Reflex Testing in NSCLC: Prof. Kerr explains the concept of reflex testing, why it’s essential in the timely and accurate diagnosis of lung cancer, and how it has transformed patient care by ensuring that crucial molecular and biomarker tests are conducted without delay. The Impact of New Treatment Options: Learn how the advent of targeted therapies and immunotherapies for NSCLC has increased the importance of reflex testing and how it’s applied in current clinical practices. Challenges and Contributions to Lung Cancer Guidelines: Prof. Kerr shares his experiences and challenges in contributing to numerous national and international lung cancer guidelines, offering a unique perspective on the evolving standards in lung cancer diagnosis and treatment. Future of Pathology and the Role of AI: Prof. Kerr also discusses the future of pathology training, especially with the integration of new technologies and artificial intelligence in diagnostics, particularly for lung cancer. Whether you're a healthcare professional, a student, or simply interested in the latest advancements in oncology, this episode offers valuable insights into the evolving field of lung cancer diagnosis and treatment.For inquiries, contact us at [email protected] Let's connect: Website: www.oncoassist.com Twitter: https://twitter.com/oncoassist LinkedIn: https://www.linkedin.com/showcase/oncoassist-oncology-decision-support-tool Instagram:https://www.instagram.com/oncoassist/ Facebook: https://www.facebook.com/ONCOassist

Welcome to another episode of the Oncology Spotlight Podcast! In this episode, we're thrilled to have Eoin Tabb, Chief 2 Pharmacist specializing in Clinical Cancer Services at University Hospital Waterford, Ireland, as our guest. Eoin is a passionate advocate for digital health transformation, leading a team dedicated to enhancing the safety and efficiency of cancer care. In this insightful conversation, Eoin shares his journey to becoming an oncology pharmacist, his specialization in cancer care, and how digital health is revolutionizing oncology today and in the future. We also dive into his work with The Irish Haematology Oncology Podcast, a jargon-free exploration of cancer care, designed to educate healthcare professionals and enthusiasts alike. Key Discussion Points: Eoin’s background and journey to becoming a pharmacist Specializing in cancer care and the reasons behind it The impact of digital health transformation on cancer care today and its future potential The inspiration and goals behind The Irish Haematology Oncology Podcast Challenges faced by oncology professionals today How digital tools are helping to address these challenges The potential opportunities for AI in oncology Eoin’s aspirations for advancing cancer care through his current role and broader initiatives Whether you’re a healthcare professional, digital health enthusiast, or simply interested in the future of cancer care, this episode offers valuable insights. 👉 Don’t forget to like, comment, and subscribe to our channel for more insightful episodes!🔔 Turn on notifications so you never miss an update. 🔗 Links: Listen to The Irish Haematology Oncology Podcast:  Connect with Eoin Tabb on LinkedIn:  For inquiries, contact us at [email protected] Let's connect: Website: www.oncoassist.com Twitter: https://twitter.com/oncoassist LinkedIn: https://www.linkedin.com/showcase/oncoassist-oncology-decision-support-tool Instagram:https://www.instagram.com/oncoassist/ Facebook: https://www.facebook.com/ONCOassist

Welcome to the Oncology Spotlight! In this episode, join us as we delve into the forefront of cancer care with Professor Gerry Hanna, a distinguished radiation oncologist and Marie Curie Chair of Clinical Oncology at Trinity College Dublin. Key Discussion Points: Introduction: Get to know Professor Gerry Hanna and his illustrious career spanning leading institutions like Queen’s University Belfast and the University of Melbourne. Latest Developments in Lung Cancer Treatment: Professor Hanna shares groundbreaking advancements shaping the future of lung cancer care. Evolution of CRT in Lung Cancer: Discover insights into how Combined Radiation Therapy (CRT) has progressed over the past five years. Interpreting Scans Post-CRT: Learn about challenges and strategies in interpreting scans, especially in conjunction with immunotherapy. Emerging Guidelines for Scan Interpretation: Professor Hanna outlines emerging best practices crucial for accurate treatment decisions. Role of Multidisciplinary Teams (MDT): Understand the pivotal role MDTs play in enhancing diagnostic accuracy and treatment planning. Current Research Initiatives: Explore ongoing research projects like PERTAIN and CONCORDE and their potential impact on cancer care. Challenges in Oncology Today: Professor Hanna discusses the significant challenges facing oncology and strategies to overcome them. Future Prospects with AI: Gain insights into the promising intersection of oncology and artificial intelligence (AI). Don't miss this enlightening conversation that promises to deepen your understanding of cutting-edge oncology practices and future directions in cancer treatment. 🎧 Listen to the full podcast episode: LINK and join the conversation!